Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 7,060.00
-590.00 (-7.71%)
At close: Apr 30, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 246.34 billion as of April 30, 2026. Its market cap has increased by 252.21% in one year.
Market Cap
246.34B
Enterprise Value
241.98B
Revenue
24.59B
Ranking
n/a
PE Ratio
n/a
Stock Price
7,060.00
Market Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 246.34B, an increase of 242.72%. That is a compound annual growth rate of 18.26%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 29, 2026 | 266.93B | 11.98% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| curacle co.,ltd. | 389.44B |
| Kangstem Biotech | 385.15B |
| TiumBio | 361.10B |
| Y-Biologics | 347.58B |
| NIBEC | 309.20B |
| Bio Solution | 295.98B |
| ABION | 236.52B |
| ViGenCell | 203.15B |